Steve Beuchaw
Stock Analyst at Morgan Stanley
(2.52)
# 2,260
Out of 4,711 analysts
104
Total ratings
62.32%
Success rate
7.03%
Average return
Main Sectors:
Stocks Rated by Steve Beuchaw
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Upgrades: Overweight | $49 → $51 | $44.67 | +14.17% | 1 | Feb 16, 2024 | |
| A Agilent Technologies | Initiates: Outperform | n/a | $134.51 | - | 20 | Dec 13, 2023 | |
| ALGN Align Technology | Maintains: Outperform | $711 → $770 | $211.06 | +264.83% | 11 | Jul 29, 2021 | |
| BRKR Bruker | Upgrades: Peer Perform | n/a | $57.00 | - | 9 | Nov 16, 2020 | |
| HSIC Henry Schein | Upgrades: Outperform | $68 | $69.82 | -2.61% | 4 | Apr 2, 2020 | |
| XRAY DENTSPLY SIRONA | Upgrades: Outperform | $66 | $18.70 | +252.94% | 6 | Apr 2, 2020 | |
| ILMN Illumina | Maintains: Equal-Weight | $320 → $288 | $136.02 | +111.73% | 9 | Jan 7, 2019 | |
| TMO Thermo Fisher | Maintains: Overweight | $254 → $260 | $524.05 | -50.39% | 7 | Oct 25, 2018 | |
| WAT Waters | Maintains: Equal-Weight | $204 → $211 | $368.16 | -42.69% | 13 | Oct 10, 2018 | |
| MYGN Myriad Genetics | Maintains: Overweight | $51 → $54 | $13.36 | +304.19% | 10 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $41 | $161.88 | -74.67% | 5 | Sep 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $327.47 | +2.30% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $325.85 | +2.81% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $19 | $30.86 | -38.43% | 5 | Aug 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $30,000 → $25,000 | $0.35 | +7,142,757.14% | 2 | Mar 15, 2017 |
Qiagen
Feb 16, 2024
Upgrades: Overweight
Price Target: $49 → $51
Current: $44.67
Upside: +14.17%
Agilent Technologies
Dec 13, 2023
Initiates: Outperform
Price Target: n/a
Current: $134.51
Upside: -
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $711 → $770
Current: $211.06
Upside: +264.83%
Bruker
Nov 16, 2020
Upgrades: Peer Perform
Price Target: n/a
Current: $57.00
Upside: -
Henry Schein
Apr 2, 2020
Upgrades: Outperform
Price Target: $68
Current: $69.82
Upside: -2.61%
DENTSPLY SIRONA
Apr 2, 2020
Upgrades: Outperform
Price Target: $66
Current: $18.70
Upside: +252.94%
Illumina
Jan 7, 2019
Maintains: Equal-Weight
Price Target: $320 → $288
Current: $136.02
Upside: +111.73%
Thermo Fisher
Oct 25, 2018
Maintains: Overweight
Price Target: $254 → $260
Current: $524.05
Upside: -50.39%
Waters
Oct 10, 2018
Maintains: Equal-Weight
Price Target: $204 → $211
Current: $368.16
Upside: -42.69%
Myriad Genetics
Oct 10, 2018
Maintains: Overweight
Price Target: $51 → $54
Current: $13.36
Upside: +304.19%
Sep 28, 2018
Maintains: Overweight
Price Target: $21 → $41
Current: $161.88
Upside: -74.67%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $327.47
Upside: +2.30%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $325.85
Upside: +2.81%
Aug 31, 2018
Maintains: Underweight
Price Target: $21 → $19
Current: $30.86
Upside: -38.43%
Mar 15, 2017
Downgrades: Underweight
Price Target: $30,000 → $25,000
Current: $0.35
Upside: +7,142,757.14%